Published in Boll Soc Ital Biol Sper on September 30, 1983
Prenatal origin of acute lymphoblastic leukaemia in children. Lancet (1999) 4.21
Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet (1998) 3.91
Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection. Leukemia (2005) 3.09
Structure and origin of the acute promyelocytic leukemia myl/RAR alpha cDNA and characterization of its retinoid-binding and transactivation properties. Oncogene (1991) 2.86
IL-1 stimulates IL-6 production in endothelial cells. J Immunol (1989) 2.85
Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS) Blood (1997) 2.40
Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia (2009) 2.30
Juvenile myelomonocytic leukemia. Blood (1997) 2.19
Acute promyelocytic leukemia: from genetics to treatment. Blood (1994) 2.09
Translocation breakpoint of acute promyelocytic leukemia lies within the retinoic acid receptor alpha locus. Proc Natl Acad Sci U S A (1991) 1.90
Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. Leukemia (2009) 1.86
Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL. Leukemia (1999) 1.83
Recombinant human interleukin 5 is a selective eosinophil chemoattractant. Eur J Immunol (1989) 1.80
Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting. Leukemia (2007) 1.79
North-South twinning in paediatric haemato-oncology: the La Mascota programme, Nicaragua. Lancet (1998) 1.75
Transplacental chemical exposure and risk of infant leukemia with MLL gene fusion. Cancer Res (2001) 1.70
Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. Leukemia (2003) 1.64
Monokine production by microglial cell clones. Eur J Immunol (1989) 1.64
Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia (2006) 1.60
Treatment of childhood Hodgkin's disease with COPP or COPP-ABV (hybrid) without radiotherapy in Nicaragua. Ann Oncol (1997) 1.58
The MLL recombinome of acute leukemias. Leukemia (2006) 1.51
Biological and clinical features of acute lymphoblastic leukaemia with cytoplasmic granules or inclusions: description of eight cases. Br J Haematol (1989) 1.49
Allogeneic bone marrow stem cell transplantation following CD34+ immunomagnetic enrichment in patients with inherited metabolic storage diseases. Bone Marrow Transplant (2003) 1.47
Rearrangements and aberrant expression of the retinoic acid receptor alpha gene in acute promyelocytic leukemias. J Exp Med (1990) 1.47
Combined microwave thermal ablation and liver resection for single step treatment of otherwise unresectable colorectal liver metastases; a monoistitutional experiences. Eur Rev Med Pharmacol Sci (2014) 1.42
Heart rate variability and myocardial infarction: systematic literature review and metanalysis. Eur Rev Med Pharmacol Sci (2009) 1.39
Acute undifferentiated leukemia with CD7+ and CD13+ immunophenotype. Lack of molecular lineage commitment and association with poor prognostic features. Cancer (1992) 1.39
Laparoscopic enucleation of a jejunal mesenteric cyst: a case report. Clin Ter (2010) 1.38
Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies. Hum Gene Ther (2000) 1.34
Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis (1997) 1.34
Stent conformity in curved vascular models with simulated aneurysm necks using flat-panel CT: an in vitro study. AJNR Am J Neuroradiol (2007) 1.32
Flow-diverter silk stent for the treatment of intracranial aneurysms: 1-year follow-up in a multicenter study. AJNR Am J Neuroradiol (2012) 1.29
Surface membrane heterogeneity among human mononuclear phagocytes. J Immunol (1984) 1.27
Molecular analysis of the progression from Helicobacter pylori-associated chronic gastritis to mucosa-associated lymphoid-tissue lymphoma of the stomach. N Engl J Med (1998) 1.26
Treatment of a recurrent traumatic carotid-cavernous fistula: vertebro-basilar approach after surgical occlusion of the internal carotid artery. Neuroradiology (1988) 1.25
Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of MLL gene rearrangement. Leukemia (2007) 1.25
Ratio of metastatic lymph nodes: impact on staging and survival of gastric cancer. Eur J Surg Oncol (2007) 1.24
Expression pattern of the RAR alpha-PML fusion gene in acute promyelocytic leukemia. Proc Natl Acad Sci U S A (1992) 1.24
Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol. Leukemia (2009) 1.24
Major complications of percutaneous embolization of skull-base tumors. AJNR Am J Neuroradiol (1999) 1.23
Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. Lancet (2001) 1.21
Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Blood (1999) 1.20
Endovascular treatment of brain arteriovenous malformations using a liquid embolic agent: results of a prospective, multicentre study (BRAVO). Eur Radiol (2013) 1.19
RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML). Leukemia (1999) 1.18
A new morphologic classification system for acute promyelocytic leukemia distinguishes cases with underlying PLZF/RARA gene rearrangements. Blood (2000) 1.18
Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia. Leukemia (2012) 1.16
Clonality profile in relapsed precursor-B-ALL children by GeneScan and sequencing analyses. Consequences on minimal residual disease monitoring. Leukemia (2003) 1.16
Direct induction of tissue factor synthesis by endotoxin in human macrophages from diverse anatomical sites. Immunology (1983) 1.15
The paired box domain gene PAX5 is fused to ETV6/TEL in an acute lymphoblastic leukemia case. Cancer Res (2001) 1.13
Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease. Hum Gene Ther (2004) 1.13
Immunocytochemical diagnosis of acute promyelocytic leukemia (M3) with the monoclonal antibody PG-M3 (anti-PML). Blood (1997) 1.12
Fusion of ETV6 to the caudal-related homeobox gene CDX2 in acute myeloid leukemia with the t(12;13)(p13;q12). Blood (1999) 1.11
Phenotypic characterization of human T lymphocyte populations producing macrophage-activating factor (MAF) lymphokines. J Immunol (1984) 1.10
In Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against CD33 Acute Myeloid Leukemia. Adv Hematol (2012) 1.09
A possible autocrine role for interleukin-6 in two lymphoma cell lines. Blood (1989) 1.09
CD99 expression in T-lineage ALL: implications for flow cytometric detection of minimal residual disease. Leukemia (2004) 1.09
Prolonged survival of B-lineage acute lymphoblastic leukemia cells is accompanied by overexpression of bcl-2 protein. Blood (1993) 1.09
Infant acute leukemias show the same biased distribution of ALL1 gene breaks as topoisomerase II related secondary acute leukemias. Cancer Res (1997) 1.09
Extramedullary involvement in patients with acute promyelocytic leukemia: a report of seven cases. Cancer (1998) 1.08
Secretory phospholipases A2 induce beta-glucuronidase release and IL-6 production from human lung macrophages. J Immunol (2000) 1.08
The tyrosine kinase abl-related gene ARG is fused to ETV6 in an AML-M4Eo patient with a t(1;12)(q25;p13): molecular cloning of both reciprocal transcripts. Blood (1999) 1.07
Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia. Leukemia (2008) 1.07
Heteroduplex analysis of T-cell receptor gamma gene rearrangements for diagnosis and monitoring of cutaneous T-cell lymphomas. Blood (1994) 1.07
Gadolinium-enhanced MR of chronic dural sinus thrombosis. AJNR Am J Neuroradiol (1995) 1.06
Inhibition of natural killer activity by human bronchoalveolar macrophages. J Immunol (1982) 1.05
Venous aneurysms of saphena magna: is this really a rare disease? : Comment to: A challenging hernia: primary venous aneurysm of the proximal saphenous vein. Hernia (2012) 1.05
Implementation of array based whole-genome high-resolution technologies confirms the absence of secondary copy-number alterations in MLL-AF4-positive infant ALL patients. Leukemia (2010) 1.05
Functional characterization of high levels of meningioma 1 as collaborating oncogene in acute leukemia. Leukemia (2010) 1.05
Cerebral dural arteriovenous fistulas: percutaneous transvenous embolization. Radiology (1996) 1.05
Biased distribution of chromosomal breakpoints involving the MLL gene in infants versus children and adults with t(4;11) ALL. Oncogene (2001) 1.04
Genetic polymorphism of NAD(P)H:quinone oxidoreductase is associated with an increased risk of infant acute lymphoblastic leukemia without MLL gene rearrangements. Leukemia (2005) 1.04
DNA copy-number abnormalities do not occur in infant ALL with t(4;11)/MLL-AF4. Leukemia (2009) 1.03
Familial partial monosomy 7 and myelodysplasia: different parental origin of the monosomy 7 suggests action of a mutator gene. Cancer Genet Cytogenet (2001) 1.02
Delineation of multiple deleted regions in 7q in myeloid disorders. Genes Chromosomes Cancer (1999) 1.02
Is supercomplex organization of the respiratory chain required for optimal electron transfer activity? Biochim Biophys Acta (2008) 1.02
Expression of myeloid markers lacks prognostic impact in children treated for acute lymphoblastic leukemia: Italian experience in AIEOP-ALL 88-91 studies. Blood (1998) 1.02
Phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non-small-cell lung cancer. J Clin Oncol (1999) 1.01
Molecular evaluation of response to all-trans-retinoic acid therapy in patients with acute promyelocytic leukemia. Blood (1991) 1.00
The amino terminus targets the mixed lineage leukemia (MLL) protein to the nucleolus, nuclear matrix and mitotic chromosomal scaffolds. Leukemia (2000) 0.99
The EuroChimerism concept for a standardized approach to chimerism analysis after allogeneic stem cell transplantation. Leukemia (2012) 0.99
Modulation of cell cycle by graded expression of MLL-AF4 fusion oncoprotein. Leukemia (2004) 0.99
Magnetic resonance in multiple sclerosis. Neuroradiology (1986) 0.98
Mesenchymal stromal cells for the treatment of graft-versus-host disease: understanding the in vivo biological effect through patient immune monitoring. Leukemia (2012) 0.98
Effect of Aplidin in acute lymphoblastic leukaemia cells. Br J Cancer (2003) 0.98
Response to neoadjuvant chemotherapy and effects of tumor regression in gastric cancer. Eur J Surg Oncol (2006) 0.98
Immunophenotype of adult and childhood acute promyelocytic leukaemia: correlation with morphology, type of PML gene breakpoint and clinical outcome. A cooperative Italian study on 196 cases. Br J Haematol (1998) 0.96
Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study. Leukemia (2009) 0.96
The seventh international childhood acute lymphoblastic leukemia workshop report: Palermo, Italy, January 29--30, 2005. Leukemia (2005) 0.95